Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine
Efforts to resolve the contradictions in early diagnosis of prostate cancer: a comparison of different algorithms of sarcosine in urine
复制标题
努力解决前列腺癌早期诊断的矛盾：尿液肌氨酸不同算法的比较
DOI：
10.1038/pcan.2011.2
复制
发表时间：
2011-06-01
影响因子：
4.8
通讯作者：
Yao, X-D
中科院分区：
文献类型：
--
作者：
Cao, D-L;Ye, D-W;Yao, X-D
肌氨酸作为前列腺癌（PCa）检测的有前途的生物标志物存在争议的数据。目的是澄清这些差异，并重新评估肌氨酸在PCa中的潜在价值。采用液相色谱/串联质谱法对71例未经治疗的PCa患者、39例无恶性肿瘤（NEM）患者和20例健康女性和男性尿液样本中的肌氨酸算法（上清和沉积物肌氨酸/肌酐、上清和沉积物log2（肌氨酸/丙氨酸））进行定量分析。尽管任何肌氨酸算法在PCa患者中都明显高于NEM患者（均P< 0.05），但在健康女性和男性中测量的肌氨酸值相当。此外，活检Gleason评分和临床t分期均与肌氨酸算法无关（均P < 0.05），受试者工作特征曲线分析表明，任何肌氨酸算法的诊断能力均不显著高于血清和尿液PSA，但不显著低于前列腺癌抗原3 （PCA3）和无PSA百分比（% fPSA）。当任何一种sarcos算法与PCA3或% fPSA结合时，可以观察到诊断性能的提高。总之，与PCA3和% fPSA相比，肌氨酸在PCa中的预测能力是适度的。肌氨酸在进入临床之前还需要更多的验证，它可能被列入候选PCa生物标志物的列表中。
Controversial data on sarcosine as a promising biomarker for prostate cancer (PCa) detection are present. The objective was to clarify these discrepancies and reevaluate the potential value of sarcosine in PCa. Sarcosine algorithms (supernatant and sediment sarcosine/creatinine, supernatant and sediment log2 (sarcosine/alanine)) in urine samples from 71 untreated patients with PCa, 39 patients with no evidence of malignancy (NEM) and 20 healthy women and men were quantified by liquid chromatography/tandem mass spectrometry. Although any sarcosine algorithms were significantly higher in PCa patients than in NEM patients (all P< 0.05), comparable sarcosine values were measured in healthy women and men. Additionally, neither biopsy Gleason score nor clinical T-stage were correlated with sarcosine algorithms (all P> 0.05), and receiver operating characteristic curve analysis indicated that the diagnostic power of any of sarcosine algorithms was nonsignificantly higher than that of serum and urine PSA, but nonsignificantly lower than prostate cancer antigen 3 (PCA3) and the percent-free PSA (% fPSA). Improved diagnostic performances were observed when any of sarcosine algorithms was combined with PCA3 or% fPSA. In conclusion, the predictive power of sarcosine in PCa is modest compared with PCA3 and% fPSA. Sarcosine, which awaits more validation before it reaches the clinic, could be included into the list of candidate PCa biomarkers.